Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gilteritinib”

55 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 55 results

Testing effectiveness (Phase 2)WithdrawnNCT05279859
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Erasca, Inc.
Testing effectiveness (Phase 2)Study completedNCT03730012
What this trial is testing

ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Global Development, Inc. 11
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06652685
What this trial is testing

Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
Ruijin Hospital 218
Testing effectiveness (Phase 2)Looking for participantsNCT06561880
What this trial is testing

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Who this might be right for
FLT3 Gene MutationAML
Institute of Hematology & Blood Diseases Hospital, China 66
Early research (Phase 1)Study completedNCT02571816
What this trial is testing

Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215

Who this might be right for
Hepatic ImpairmentHealthy
Astellas Pharma Global Development, Inc. 24
Early research (Phase 1)Study completedNCT03964038
What this trial is testing

Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects

Who this might be right for
Healthy Volunteer
Astellas Pharma Global Development, Inc. 48
Not applicableUnknownNCT05791890
What this trial is testing

GilteRInf 2022 Study (Gilteritinib Related Infections)

Who this might be right for
Acute Myeloid Leukemia
University of Rome Tor Vergata 78
Not applicableStudy completedNCT06734585
What this trial is testing

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Who this might be right for
Acute Myeloid Leukemia
Astellas Pharma Singapore Pte. Ltd. 114
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Not applicableNo Longer AvailableNCT03315299
What this trial is testing

Individual Patient Expanded Access Gilteritinib (ASP2215)

Who this might be right for
AML
Etan Orgel
Not applicableNo Longer AvailableNCT03409081
What this trial is testing

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Who this might be right for
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04240002
What this trial is testing

Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Astellas Pharma Global Development, Inc. 9
Early research (Phase 1)Study completedNCT04699877
What this trial is testing

Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Who this might be right for
Renal ImpairedGilteritinibNormal Renal Function+1 more
Astellas Pharma Global Development, Inc. 17
Early research (Phase 1)Looking for participantsNCT05756777
What this trial is testing

Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center 18
Large-scale testing (Phase 3)Looking for participantsNCT07463651
What this trial is testing

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Who this might be right for
Acute Myeloid Leukemia (AML)FLT3-ITD MutationAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University 594
Testing effectiveness (Phase 2)Study completedNCT03836209
What this trial is testing

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
PrECOG, LLC. 181
Large-scale testing (Phase 3)Study completedNCT02421939
What this trial is testing

ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Who this might be right for
Leukemia, Acute Myeloid (AML)
Astellas Pharma Global Development, Inc. 371
Early research (Phase 1)Looking for participantsNCT06222580
What this trial is testing

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+2 more
Uma Borate 30
Testing effectiveness (Phase 2)Looking for participantsNCT07259707
What this trial is testing

Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML

Who this might be right for
Acute Myeloid LeukemiaFLT3 Internal Tandem Duplication PositiveIntermediate Risk Acute Myeloid Leukemia+1 more
First Affiliated Hospital of Zhejiang University 25
Testing effectiveness (Phase 2)Study completedNCT02014558
What this trial is testing

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 265
Next Page